Shares of Metsera Inc. (NASDAQ:MTSR - Get Free Report) traded up 10.3% on Wednesday . The stock traded as high as $29.65 and last traded at $29.64. 377,738 shares traded hands during trading, a decline of 59% from the average session volume of 912,665 shares. The stock had previously closed at $26.88.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the stock. Guggenheim boosted their price target on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Wells Fargo & Company assumed coverage on shares of Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $55.00.
Get Our Latest Analysis on Metsera
Metsera Stock Performance
The stock's 50-day moving average price is $27.47.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Strs Ohio acquired a new position in Metsera in the first quarter valued at about $76,000. New York State Common Retirement Fund acquired a new position in Metsera in the first quarter valued at about $131,000. Corebridge Financial Inc. purchased a new stake in Metsera during the first quarter worth about $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Metsera during the first quarter worth about $248,000. Finally, MetLife Investment Management LLC acquired a new stake in shares of Metsera during the first quarter worth about $254,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
